Some studies have provided evidence that BCI has yielded favorable outcomes when employed on various types of tumor cells through the DUSP6-dependent pathway, while others suggested that the anticancer activity may not result from DUSP6 inhibition [14]. The gene discussed is DUSP6; the disease is neoplasm.